CRESCENT BIOPHARMA, INC. Increase (Decrease) in Contract with Customer, Liability
CRESCENT BIOPHARMA, INC. (CBIO) reported Increase (Decrease) in Contract with Customer, Liability of -$1.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00.
- CRESCENT BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.04M.
- CRESCENT BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was $0.00.
- CRESCENT BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $0.00.
- CRESCENT BIOPHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $4.16M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$1.04M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | -$1.04M 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | $4.16M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | $0.00 derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-04-29 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |